AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

INMD · NASDAQ · Medical - Devices

InMode

Builds energy-based systems for aesthetic and medical treatments in clinical practices.

$14.96

After-hours close+0.11 (+0.71%)

At close$14.86(+0.10%)

Something off on this page? Send us feedback.

Profile

InMode Ltd.INMDHealth Care

Energy-based aesthetic and medical-treatment systems are sold to physicians and practices through platforms, handpieces, consumables, and warranties. The United States is the largest reported market, while regulatory clearances, physician training, and outsourced manufacturing shape operations.

Energy-based aesthetic and medical-treatment systems are sold to physicians and clinical practices through multi-technology workstations, handpieces, consumables, and extended warranties. IgniteRF, OptimasMAX, EvolveX, EmpowerRF, and Morpheus8 organize radiofrequency, fractional RF, IPL, laser, and related applications.

The United States is the largest reported customer geography, alongside Europe and Asia. Product innovation, physician relationships and training, sales productivity, and market acceptance shape commercial execution.

Devices require ongoing regulatory compliance, including FDA clearances for products, modified products, and expanded indications. Almost all manufacturing is outsourced to a small group of subcontractors, making supplier continuity part of the operating model.

Company facts

CEOMoshe Mizrahy

ListedAug 8, 2019

ExchangeNASDAQ

HeadquartersYokne'am, Israel

CountryIsrael

Employees660

CIK0001742692

ISINIL0011595993

Key statistics

Market cap$853.6M

EPS (ttm)$1.23

P/E (ttm)12.07

ROE11.8%

P/B1.39

P/S2.28

Dividend yield—

Beta0.73vs XLV 0.38

Year to date +0.4% · Average volume (30d) 448.1K

Analysts

Price target, next 12 months$19.00+27.9%Median of 11 analysts · vs the Aug 28 close

ConsensusHold5 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $14.85

High$19.00+27.9%

Median$19.00+27.9%

Low$19.00+27.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
May 7, 2026	Barclays	Reiterate		Overweight	$27	$19
Feb 11, 2026	Robert W. Baird	Target				$17
Dec 17, 2025	Canaccord Genuity	Reiterate		Hold	$16	$15
Apr 29, 2025	BTIG	Downgrade	Buy	Neutral

Earnings

EPS

Estimate$0.32

ReportedDue Oct 28, 2026

Revenue

Estimate$91.6M

ReportedDue Oct 28, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.35	$0.35	+1.2%	$93.7M	$95.6M	+2.0%	+1.26%
Aug 5, 2026Q2 FY26	$0.35	$0.35	+1.2%	$94.9M	$95.4M	+0.6%	−1.04%
May 6, 2026Q1 FY26	$0.30	$0.25	−16.1%	$79.8M	$82.0M	+2.7%	+2.43%
Feb 10, 2026Q4 FY25	$0.42	$0.46	+10.5%	$101.5M	$103.9M	+2.3%	−2.60%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$77.9M	$95.6M	$93.2M	$103.9M	$82.0M	$95.6M
Gross profit	$60.9M	$76.5M	$72.3M	$81.3M	$61.6M	$71.5M
Operating income	$15.6M	$22.9M	$20.9M	$26.0M	$10.1M	$12.3M
Net income	$18.2M	$26.7M	$21.9M	$27.0M	$11.6M	$17.1M
Diluted EPS	$0.26	$0.42	$0.34	$0.42	$0.18	$0.29
Gross margin	78.2%	80.0%	77.6%	78.3%	75.0%	74.8%
Operating margin	20.1%	23.9%	22.4%	25.0%	12.3%	12.8%

Fiscal years (4-quarter sums)FY21 $357.6M · FY22 $454.3M · FY23 $492.0M · FY24 $394.8M · FY25 $370.5M

Revenue by product · FY25

Capital Equipment$289.1M · 100%

Revenue by geography · FY25

United States$198.7M · 54%

Europe$79.0M · 21%

Asia$49.2M · 13%

Other Country$40.2M · 11%

Israel$3.4M · 1%

Balance sheet, Jun 30, 2026Cash & short-term investments $501.1M · Total debt $4.5M · Total assets $720.3M · Shareholders' equity $629.1M

Dividends

No dividends on record.

Ownership

Institutions 56.26%32.34M sharesInsiders 13.28%7.63M sharesOther 30.46%17.51M shares

Shares outstanding 57.48M · Float 48.09M · 83.7% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Moshe Mizrahy	4.30M	7.90%	13D	Aug 5, 2026
Michael Kreindel	3.11M	5.11%	13D	Apr 9, 2026
Doma Perpetual Capital Management LLC	2.73M	4.75%	13F	Aug 12, 2026
Acadian Asset Management LLC	2.58M	4.50%	13F	Aug 13, 2026
BlackRock, Inc.	2.50M	4.34%	13F	Aug 7, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.